Sonoma Pharmaceuticals, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Sonoma Pharmaceuticals, Inc. (SNOA) on November 12, 2020. The filing addresses a determination by the Audit Committee and executive management that the Company's unaudited condensed consolidated interim financial statements for the quarter ended June 30, 2020, contain material errors and can no longer be relied upon.
Key Financial Metrics and Material Changes
The filing details specific material errors discovered during the preparation of the September 30, 2020, financial statements. These errors required a restatement of the June 30, 2020, period. The filing does not provide current period revenue, profit, or cash flow figures, but quantifies the adjustments required for the prior quarter:
- Balance Sheet Adjustments (as of June 30, 2020):
- Accounts Receivable: Overstated by $446,000.
- Prepaid Expenses: Overstated by $123,000.
- Accrued Expenses: Understated by $175,000.
- Income Statement Adjustments (Quarter ended June 30, 2020):
- Revenues: Overstated by $1,487,000.
- Cost of Revenue: Overstated by $779,000.
- Gross Profit: Overstated by $708,000.
- Total Operating Expenses: Understated by $75,000.
- Other Income (Expense): Overstated by $35,000.
- Income from Discontinued Operations: Overstated by $5,000.
- Net Impact:
- Net Income (Loss): Decreased by $753,000 to a restated figure of $240,000.
- Basic and Diluted Net Income per Common Share: Decreased by $0.41.
Cause of Errors and Management Commentary
Management identified three primary causes for the financial misstatements:
- Inadequate Reserves: Insufficient reserves were taken for wholesaler and specialty pharmacy rebates, distributor fees, and customer returns, leading to revenue overstatement.
- Recording Errors: Certain expenses were understated and not properly recorded.
- Translation Errors: Europe and Mexico financial translations on the profit and loss statement were run twice for one month, resulting in an overstatement of both revenue and expenses for that period.
The Company is currently evaluating its internal controls over financial reporting to determine if significant deficiencies or material weaknesses contributed to these errors. The Audit Committee has discussed these matters with the independent auditor, Marcum LLP.
Outlook, Risks, and Contingencies
The Company plans to file Amendment No. 1 on Form 10-Q/A for the quarter ended June 30, 2020, as soon as practicable and prior to the filing of the Form 10-Q for the quarter ended September 30, 2020. On November 16, 2020, the Company requested an extension to file the September 30, 2020, quarterly report under Rule 12b-25. Management explicitly states there can be no assurance that the review will not identify further adjustments or that the report will be filed within the prescribed time period.
Investor Verification Checklist
- Verify the filing of the Form 10-Q/A for the quarter ended June 30, 2020, to confirm the final restated financial figures.
- Monitor the status of the Form 10-Q for the quarter ended September 30, 2020, given the requested filing extension.
- Review the Company's subsequent disclosures regarding the outcome of the internal control evaluation and any identified material weaknesses.
- Confirm whether additional adjustments beyond those listed in this 8-K are identified during the ongoing audit review.